Brightside HealthvsCerebral

Brightside is a telehealth platform connecting adults to licensed psychiatric providers and therapists by video and messaging. After a free online assessment, its PrecisionRx clinical-decision-support tool analyzes your symptom pattern against large treatment-outcome datasets to suggest medication options for your prescriber to consider. Care is "measurement-based": you complete standardized PHQ-9 (depression) and GAD-7 (anxiety) questionnaires at intake and at regular intervals, so providers adjust treatment based on tracked scores rather than memory alone. Therapy uses evidence-based approaches such as CBT, supplemented by structured video lessons.

Cerebral is not a drug or device; it is a telehealth service that connects you to licensed providers online. After a brief intake assessment, you are matched with a therapist for video or phone sessions using evidence-based methods such as cognitive behavioral therapy (CBT), and/or a prescriber who can evaluate you and prescribe non-controlled psychiatric medications (commonly SSRIs and SNRIs) for conditions like depression and anxiety. The platform handles scheduling, secure messaging, and medication coordination, with prescriptions sent to your pharmacy or shipped. The therapeutic benefit comes from the underlying treatments and the provider relationship, not the app itself.

Brightside has published several peer-reviewed studies, though most are observational and authored by Brightside-affiliated researchers rather than independent randomized trials. A 2022 retrospective analysis in BMC Psychiatry of 6,248 patients who completed at least 12 weeks of medication treatment found about 90% had clinically meaningful improvement on PHQ-9 or GAD-7 and about 75% reached remission (scores below 10); in the larger intent-to-treat sample these figures were lower (roughly 74% improvement and 59% remission), and about 78.9% of patients started treatment within 4 days. A 2022 JMIR Formative Research longitudinal study of 8,581 patients reported the treatment group was about 4.3 times more likely to achieve suicidal-ideation remission (odds ratio 4.31), with a predictive model 77% accurate in classifying complete remission. Because these are single-platform, observational studies, results may not generalize and individual outcomes vary.

There are no clinical trials of Cerebral the company; the relevant evidence is for the treatments it delivers. A 2022 meta-analysis of randomized controlled trials (Giovanetti et al., Telemedicine and e-Health) found video-based psychotherapy essentially equivalent to in-person therapy for depression (Hedges g of about 0.04, i.e., no meaningful difference), with comparable dropout rates. For medication, Cipriani et al.'s 2018 Lancet network meta-analysis of 21 antidepressants found every drug studied was more effective than placebo for acute major depression, with response odds ratios ranging from about 1.37 to 2.13; the broader literature puts the average antidepressant-versus-placebo effect in the modest range (standardized mean difference roughly 0.30). So the modalities Cerebral uses are well supported, while the size of the benefit is moderate and quality depends heavily on your individual provider.

Brightside itself is a care-delivery service, so "side effects" come from the prescribed medications, typically SSRIs, SNRIs, or bupropion. Common, often temporary effects include nausea, headache, drowsiness or insomnia, dry mouth, dizziness, sexual dysfunction, and appetite or weight changes. Serious but rarer risks include serotonin syndrome, abnormal bleeding, hyponatremia, and worsening mood or new or increased suicidal thoughts, which carry an FDA boxed warning for antidepressants in people under 25, especially early in treatment or after dose changes. Bupropion can lower the seizure threshold. Seek urgent help for suicidal thoughts, severe agitation, or signs of an allergic reaction, and discuss your full medication list and history with your prescriber.

Therapy itself carries little physical risk, though some people feel temporary emotional discomfort discussing difficult topics. The main medical risks come from any prescribed medication. SSRIs and SNRIs commonly cause nausea, headache, insomnia or drowsiness, sexual dysfunction, and weight changes. Serious but less common risks include serotonin syndrome, and antidepressants carry an FDA boxed warning for increased suicidal thoughts and behavior in people under 25, especially early in treatment or after dose changes. Never stop an antidepressant abruptly, as this can cause withdrawal symptoms. Report worsening mood, agitation, or suicidal thoughts to your prescriber immediately, and call or text 988 in a crisis.

As of 2026, self-pay pricing is roughly $95/month for psychiatry (medication management), $299/month for therapy (four video sessions plus unlimited messaging), and about $349/month for combined psychiatry plus therapy. Medications are billed separately: Brightside's mail-order pharmacy is about $15 per fill or your copay if your Rx benefits are accepted, or you can use a local pharmacy or GoodRx. Brightside accepts many major insurers (Aetna, Cigna, Anthem, UnitedHealthcare, and some Medicare/Medicaid plans); with coverage, out-of-pocket can drop to typical copays (often about $15-$30 per session), though actual cost depends on your deductible and plan. Verify your specific coverage before enrolling, since billing surprises are a frequent complaint.

As of 2026, out-of-pocket prices are roughly $175 per therapy session (with discounted bundles such as about $795 for three months of regular sessions), around $60 per month for medication management (billed about $180 per quarter, with the medication itself extra), roughly $365 per month for combined medication plus therapy, and about $325 per month for couples therapy; veterans may receive a discount. With in-network insurance (Cerebral lists partners such as Aetna, Blue Cross Blue Shield, Cigna, Optum, and UnitedHealthcare), copays average around $30 per session. Prices change frequently, so confirm current rates, your coverage, and your exact copay before starting, since some users have reported surprise charges.

Brightside is for US adults (and teens 13-17 via a dedicated, therapy-first program available in select states) with depression, anxiety, and related conditions like insomnia, OCD, panic, or PTSD who are comfortable with virtual care. It is a good fit for people wanting medication management, therapy, or both without in-person visits. It is NOT appropriate if you need controlled substances (no Adderall, Xanax, Klonopin, Ativan, or other stimulants/benzodiazepines), have bipolar I or active mania, or are in an acute, life-threatening crisis requiring emergency care. People with complex or treatment-resistant conditions, substance use disorders, or psychosis are generally directed to in-person or higher-level care.

Cerebral is designed for US adults 18 and older seeking online therapy or medication management for conditions such as depression, anxiety, insomnia, and bipolar disorder; teen therapy is available in a limited set of states. It is a poor fit for anyone needing controlled substances, including stimulants for ADHD (Adderall, Vyvanse, Ritalin) or benzodiazepines (Xanax), which Cerebral stopped prescribing for most patients in 2022. It is not appropriate for psychiatric emergencies, active suicidal crisis, psychosis, or severe conditions requiring in-person or higher-level care. Anyone in crisis should call or text 988 or go to an emergency room.